Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors-Reference-Cited by-同舟云学术

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors

Published:2011-05 Issue:5 Volume:6 Page:905-912
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Koh Youngil,Kim Dong-Wan,Kim Tae Min,Lee Se-Hoon,Jeon Yoon Kyung,Chung Doo Hyun,Kim Young-Whan,Heo Dae Seog,Kim Woo-Ho,Bang Yung-Jue

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. “Oncogenic shock”: explaining oncogene addiction through differential signal attenuation;Sharma;Clin Cancer Res,2006

2. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

3. A mouse model for EML4-ALK-positive lung cancer;Soda;Proc Natl Acad Sci USA,2008

4. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer;Takeuchi;Clin Cancer Res,2009

5. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases;Cancer Reports;2024-01-11

2. Background of the need for targeted therapy options and platinum-based therapy responses in EGFR and ALK-mutated lung adenocarcinoma;Turkish Journal of Clinics and Laboratory;2023-09-30

3. The relationship between thyroid transcription factor-1 positivity and epidermal growth factor receptor mutation in lung adenocarcinoma and its prognostic significance;Eurasian Journal of Pulmonology;2023

4. Therapeutic options for lung cancer with ALK or ROS1 (+) rearrangement. First line and progression management;Revisiones en Cáncer;2023

5. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study);Journal of Cancer Research and Clinical Oncology;2022-09-01